Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Via del Pozzo, 71, 41124 Modena, Italy.
EHRA mHEALTH and Health Economics Section, European Heart Rhythm Association, Biot 06903, France.
Europace. 2022 Nov 22;24(11):1834-1843. doi: 10.1093/europace/euac142.
Since digital devices are increasingly used in cardiology for assessing cardiac rhythm and detecting arrhythmias, especially atrial fibrillation (AF), our aim was to evaluate the expectations and opinions of healthcare professionals in Europe on reimbursement policies for the use of digital devices (including wearables) in AF and other arrhythmias. An anonymous survey was proposed through announcements on the European Heart Rhythm Association website, social media channels, and mail newsletter. Two hundred and seventeen healthcare professionals participated in the survey: 32.7%, reported regular use of digital devices, 45.2% reported that they sometimes use these tools, 18.6% that they do not use but would like to. Only a minority (3.5%) reported a lack of trust in digital devices. The survey highlighted a general propensity to provide medical consultation for suspected AF or other arrhythmias detected by a consumer-initiated use of digital devices, even if time constraints and reimbursement availability emerged as important elements. More than 85% of respondents agreed that reimbursement should be applied for clinical use of digital devices, also in different settings such as post-stroke, post-cardioversion, post-ablation, and in patients with palpitations or syncope. Finally, 73.6% of respondents confirmed a lack of reimbursement fees in their country for physicians' consultations (tracings interpretation) related to digital devices. Digital devices, including wearables, are increasingly and widely used for assessing cardiac rhythm and detecting AF, but a definition of reimbursement policies for physicians' consultations is needed.
由于数字设备在心脏病学中越来越多地用于评估心脏节律和检测心律失常,尤其是心房颤动(AF),我们的目的是评估欧洲医疗保健专业人员对数字设备(包括可穿戴设备)在 AF 和其他心律失常中的使用的报销政策的期望和意见。通过在欧洲心脏病学会网站、社交媒体渠道和邮件时事通讯上发布公告,提出了一项匿名调查。有 217 名医疗保健专业人员参与了这项调查:32.7%的人报告经常使用数字设备,45.2%的人报告有时使用这些工具,18.6%的人不使用但希望使用。只有少数(3.5%)人报告对数字设备缺乏信任。调查突出了一种普遍倾向,即在消费者发起使用数字设备检测到疑似 AF 或其他心律失常时,提供医疗咨询,即使时间限制和报销可用性成为重要因素。超过 85%的受访者同意应将数字设备的临床使用纳入报销范围,即使在不同的环境中,如中风后、电击复律后、消融后,以及在有心悸或晕厥的患者中。最后,73.6%的受访者证实,他们所在国家的医生咨询(描记解读)相关的数字设备报销费用不足。数字设备,包括可穿戴设备,越来越广泛地用于评估心脏节律和检测 AF,但需要制定医生咨询报销政策的定义。